AtriCure ( ATRC ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, July 29, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
AtriCure ( ATRC ) Q2 Revenue Jumps 17%
AtriCure ( NASDAQ:ATRC ) , a medical device company specializing in cardiac surgical technologies, delivered its earnings release on July 29, 2025, reporting results that outpaced Wall Street consensus estimates. The company posted revenue of $136.1 million ( GAAP ) , ahead of the $130.2 million ...
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Antelope Ent Hldgs ( NASDAQ:AEHL ) , AtriCure ( NASDAQ:ATRC )
Shares of LendingClub Corporation LC rose sharply in pre-market trading after the company reported better-than-expected second-quarter sales results. LendingClub reported a strong second-quarter performance, with a 156% increase in net income.
AtriCure ( ATRC ) Reports Q2 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of +86.67% and +4.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Abbott ( ABT ) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) delivered earnings and revenue surprises of +0.80% and +0.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Has Amneal Pharmaceuticals ( AMRX ) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Astellas Pharma ( ALPMY ) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
Is Astellas Pharma ( ALPMY ) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
Does AtriCure ( ATRC ) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - AtriCure ( NASDAQ:ATRC ) , Airbnb ( NASDAQ:ABNB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised Visa Inc. V price target from $383 to $384.
AtriCure ( ATRC ) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of 44% and 0.16%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre ( LMAT ) Soars 7.7%: Is Further Upside Left in the Stock?
LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neogen ( NEOG ) Lags Q3 Earnings and Revenue Estimates
Neogen (NEOG) delivered earnings and revenue surprises of -23.08% and 0.92%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?
AtriCure ( ATRC ) Upgraded to Buy: Here's What You Should Know
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is AnaptysBio ( ANAB ) Stock Outpacing Its Medical Peers This Year?
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
AtriCure ( ATRC ) Reports Q4 Loss, Lags Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of 46.67% and 0.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for AtriCure ( ATRC ) Q4 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Earnings Preview: Bio-Rad Laboratories ( BIO ) Q4 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will AtriCure ( ATRC ) Report Negative Earnings Next Week? What You Should Know
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apple To $183? Here Are 10 Top Analyst Forecasts For Wednesday - Apple ( NASDAQ:AAPL ) , Avino Silver & Gold Mines ( AMEX:ASM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities raised the price target for Netflix, Inc. NFLX from $1,000 to $1,175.
Brainsway ( BWAY ) Moves 8.0% Higher: Will This Strength Last?
Brainsway (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday - Snap ( NYSE:SNAP )
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of Snap Inc. SNAP gained 13.5% to $12.38 following better-than-expected quarterly financial results. Snap reported third-quarter revenue of $1.373 billion, beating the consensus estimate of $1.358 ...
AtriCure ( ATRC ) Reports Q3 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of 15% and 2.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
AtriCure's AtriClip Receives Expanded CE-Mark Indication - AtriCure ( NASDAQ:ATRC )
AtriCure, Inc. ATRC recently announced the receipt of an expanded indication for the AtriClip in CE-marked countries in Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage ( LAA ) exclusion is warranted.
AtriCure's ( ATRC ) AtriClip Receives Expanded CE-Mark Indication
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
AtriCure ( ATRC ) Reports Q2 Loss, Lags Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -13.33% and 0.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure ( ATRC ) Gains China Approval for AtriClip LAA System
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
Abbott ( ABT ) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 0.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain
After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indications
AtriCure ( ATRC ) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -19.05% and 2.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure's ( ATRC ) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
AtriCure ( NASDAQ:ATRC ) Downgraded by StockNews.com
AtriCure ( NASDAQ:ATRC - Get Free Report ) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Wednesday. A number of other research analysts also recently commented on the company.
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
Paris, France and Munich, Germany, March 25, 2024 - TRiCares SAS ( "TRiCares" ) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer ( CEO ) .
AtriCure ( NASDAQ:ATRC ) Rating Increased to Hold at StockNews.com
AtriCure ( NASDAQ:ATRC - Get Free Report ) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a report released on Tuesday. Several other research analysts also recently commented on the company.
AtriCure ( NASDAQ:ATRC ) Lowered to "Sell" at StockNews.com
StockNews.com cut shares of AtriCure ( NASDAQ:ATRC - Free Report ) from a hold rating to a sell rating in a research report sent to investors on Monday morning. Several other analysts have also weighed in on the company.
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday - AtriCure ( NASDAQ:ATRC ) , ARM Holdings ( NASDAQ:ARM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Toast, Inc. TOST from $18 to $20.
AtriCure ( ATRC ) Reports Q4 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to AtriCure ( ATRC ) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of AtriCure (ATRC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Wall Street Analysts Predict a 36.34% Upside in AtriCure ( ATRC ) : Here's What You Should Know
The consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AtriCure ( NASDAQ:ATRC ) Upgraded at StockNews.com
AtriCure ( NASDAQ:ATRC - Get Free Report ) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Thursday. ATRC has been the subject of a number of other research reports.
All You Need to Know About AtriCure ( ATRC ) Rating Upgrade to Buy
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
StockNews.com Lowers AtriCure ( NASDAQ:ATRC ) to Sell
AtriCure ( NASDAQ:ATRC - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Wednesday. Other research analysts have also issued research reports about the company.
Stocks to own ahead of a rally that this $15 billion fund house says is coming soon
Sit Investment Associates, Roger Sit, says a short sharp recession is coming, along with a stock rally and lots of opportunities to own names across the board.
AtriCure ( NASDAQ:ATRC ) Stock Rating Lowered by StockNews.com
AtriCure ( NASDAQ:ATRC - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Friday. ATRC has been the subject of a number of other reports.
AtriCure ( NASDAQ:ATRC ) Coverage Initiated by Analysts at StockNews.com
AtriCure ( NASDAQ:ATRC ) Coverage Initiated by Analysts at ... Defense World ...
Electrophysiology Catheters Market size to grow by USD 2.24 billion from 2022-2027| Abbott Laboratories, Acutus ... - PR Newswire
Electrophysiology Catheters Market size to grow by USD 2.24 billion from 2022-2027| Abbott Laboratories, Acutus ... PR ...
Stock Upgrades: AtriCure Shows Rising Relative Strength
AtriCure ( ATRC ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 62 to 75. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique rating tracks market leadership with a 1 ( worst ) ...
